Emergence potential of sylvatic dengue virus type 4 in the urban transmission cycle is restrained by vaccination and homotypic immunity

Anna P. Durbin, Sandra V. Mayer, Shannan Rossi, Irma Y. Amaya-Larios, Jose Ramos-Castaneda, Eng Eong Ooi, M. Jane Cardosa, Jorge L. Munoz-Jordan, Robert B. Tesh, William B. Messer, Scott Weaver, Nikos Vasilakis

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Sylvatic dengue viruses (DENV) are both evolutionarily and ecologically distinct from human DENV and are maintained in an enzootic transmission cycle. Evidence of sylvatic human infections from West Africa and Southeast Asia suggests that sylvatic DENV come into regular contact with humans. Thus, this potential of emergence into the human transmission cycle could limit the potential for eradicating this cycle with vaccines currently in late stages of development. We assessed the likelihood of sylvatic DENV-4 emergence in the face of natural immunity to current human strains and vaccination with two DENV-4 vaccine candidates. Our data indicate homotypic neutralization of sylvatic and human DENV-4 strains by human primary convalescent and vaccinee sera but limited heterotypic immunity. These results suggest that emergence of sylvatic strains into the human cycle would be limited by homotypic immunity mediated by virus neutralizing antibodies produced by natural infection or vaccination.

Original languageEnglish (US)
Pages (from-to)34-41
Number of pages8
JournalVirology
Volume439
Issue number1
DOIs
StatePublished - Apr 25 2013

Fingerprint

Dengue Virus
Immunity
Vaccination
Vaccines
Southeastern Asia
Western Africa
Infection
Neutralizing Antibodies
Innate Immunity
Viruses
Serum

Keywords

  • Antigenic relationships
  • Dengue virus (DENV)
  • Human DENV
  • Plaque reduction neutralization test (PRNT)
  • Sylvatic DENV
  • Vaccine

ASJC Scopus subject areas

  • Virology

Cite this

Emergence potential of sylvatic dengue virus type 4 in the urban transmission cycle is restrained by vaccination and homotypic immunity. / Durbin, Anna P.; Mayer, Sandra V.; Rossi, Shannan; Amaya-Larios, Irma Y.; Ramos-Castaneda, Jose; Eong Ooi, Eng; Jane Cardosa, M.; Munoz-Jordan, Jorge L.; Tesh, Robert B.; Messer, William B.; Weaver, Scott; Vasilakis, Nikos.

In: Virology, Vol. 439, No. 1, 25.04.2013, p. 34-41.

Research output: Contribution to journalArticle

Durbin, AP, Mayer, SV, Rossi, S, Amaya-Larios, IY, Ramos-Castaneda, J, Eong Ooi, E, Jane Cardosa, M, Munoz-Jordan, JL, Tesh, RB, Messer, WB, Weaver, S & Vasilakis, N 2013, 'Emergence potential of sylvatic dengue virus type 4 in the urban transmission cycle is restrained by vaccination and homotypic immunity', Virology, vol. 439, no. 1, pp. 34-41. https://doi.org/10.1016/j.virol.2013.01.018
Durbin, Anna P. ; Mayer, Sandra V. ; Rossi, Shannan ; Amaya-Larios, Irma Y. ; Ramos-Castaneda, Jose ; Eong Ooi, Eng ; Jane Cardosa, M. ; Munoz-Jordan, Jorge L. ; Tesh, Robert B. ; Messer, William B. ; Weaver, Scott ; Vasilakis, Nikos. / Emergence potential of sylvatic dengue virus type 4 in the urban transmission cycle is restrained by vaccination and homotypic immunity. In: Virology. 2013 ; Vol. 439, No. 1. pp. 34-41.
@article{c43cc61fe1254cfda32373dda196a071,
title = "Emergence potential of sylvatic dengue virus type 4 in the urban transmission cycle is restrained by vaccination and homotypic immunity",
abstract = "Sylvatic dengue viruses (DENV) are both evolutionarily and ecologically distinct from human DENV and are maintained in an enzootic transmission cycle. Evidence of sylvatic human infections from West Africa and Southeast Asia suggests that sylvatic DENV come into regular contact with humans. Thus, this potential of emergence into the human transmission cycle could limit the potential for eradicating this cycle with vaccines currently in late stages of development. We assessed the likelihood of sylvatic DENV-4 emergence in the face of natural immunity to current human strains and vaccination with two DENV-4 vaccine candidates. Our data indicate homotypic neutralization of sylvatic and human DENV-4 strains by human primary convalescent and vaccinee sera but limited heterotypic immunity. These results suggest that emergence of sylvatic strains into the human cycle would be limited by homotypic immunity mediated by virus neutralizing antibodies produced by natural infection or vaccination.",
keywords = "Antigenic relationships, Dengue virus (DENV), Human DENV, Plaque reduction neutralization test (PRNT), Sylvatic DENV, Vaccine",
author = "Durbin, {Anna P.} and Mayer, {Sandra V.} and Shannan Rossi and Amaya-Larios, {Irma Y.} and Jose Ramos-Castaneda and {Eong Ooi}, Eng and {Jane Cardosa}, M. and Munoz-Jordan, {Jorge L.} and Tesh, {Robert B.} and Messer, {William B.} and Scott Weaver and Nikos Vasilakis",
year = "2013",
month = "4",
day = "25",
doi = "10.1016/j.virol.2013.01.018",
language = "English (US)",
volume = "439",
pages = "34--41",
journal = "Virology",
issn = "0042-6822",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Emergence potential of sylvatic dengue virus type 4 in the urban transmission cycle is restrained by vaccination and homotypic immunity

AU - Durbin, Anna P.

AU - Mayer, Sandra V.

AU - Rossi, Shannan

AU - Amaya-Larios, Irma Y.

AU - Ramos-Castaneda, Jose

AU - Eong Ooi, Eng

AU - Jane Cardosa, M.

AU - Munoz-Jordan, Jorge L.

AU - Tesh, Robert B.

AU - Messer, William B.

AU - Weaver, Scott

AU - Vasilakis, Nikos

PY - 2013/4/25

Y1 - 2013/4/25

N2 - Sylvatic dengue viruses (DENV) are both evolutionarily and ecologically distinct from human DENV and are maintained in an enzootic transmission cycle. Evidence of sylvatic human infections from West Africa and Southeast Asia suggests that sylvatic DENV come into regular contact with humans. Thus, this potential of emergence into the human transmission cycle could limit the potential for eradicating this cycle with vaccines currently in late stages of development. We assessed the likelihood of sylvatic DENV-4 emergence in the face of natural immunity to current human strains and vaccination with two DENV-4 vaccine candidates. Our data indicate homotypic neutralization of sylvatic and human DENV-4 strains by human primary convalescent and vaccinee sera but limited heterotypic immunity. These results suggest that emergence of sylvatic strains into the human cycle would be limited by homotypic immunity mediated by virus neutralizing antibodies produced by natural infection or vaccination.

AB - Sylvatic dengue viruses (DENV) are both evolutionarily and ecologically distinct from human DENV and are maintained in an enzootic transmission cycle. Evidence of sylvatic human infections from West Africa and Southeast Asia suggests that sylvatic DENV come into regular contact with humans. Thus, this potential of emergence into the human transmission cycle could limit the potential for eradicating this cycle with vaccines currently in late stages of development. We assessed the likelihood of sylvatic DENV-4 emergence in the face of natural immunity to current human strains and vaccination with two DENV-4 vaccine candidates. Our data indicate homotypic neutralization of sylvatic and human DENV-4 strains by human primary convalescent and vaccinee sera but limited heterotypic immunity. These results suggest that emergence of sylvatic strains into the human cycle would be limited by homotypic immunity mediated by virus neutralizing antibodies produced by natural infection or vaccination.

KW - Antigenic relationships

KW - Dengue virus (DENV)

KW - Human DENV

KW - Plaque reduction neutralization test (PRNT)

KW - Sylvatic DENV

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84874959601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874959601&partnerID=8YFLogxK

U2 - 10.1016/j.virol.2013.01.018

DO - 10.1016/j.virol.2013.01.018

M3 - Article

VL - 439

SP - 34

EP - 41

JO - Virology

JF - Virology

SN - 0042-6822

IS - 1

ER -